Lyra Therapeutics (LYRA) Net Cash Flow (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Net Cash Flow of -$6.2 million in Q4 2025, up 20.27% on a QoQ basis from -$7.7 million in Q3 2025, and down 136.73% YoY from $16.8 million in Q4 2024.
Lyra Therapeutics (LYRA) Net Cash Flow (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Net Cash Flow for 7 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2025.
- Net Cash Flow for Q4 2025 came in at -$6.2 million, down 136.73% year-over-year; the trailing twelve-month figure through Dec 2025 was -$29.3 million (down 255.77% YoY), and the FY2025 annual result was -$24.7 million, down 231.12% from the prior year.
- Net Cash Flow for Q4 2025 stood at -$6.2 million, up from -$7.7 million in the prior quarter.
- The five-year high for Net Cash Flow was $88.0 million in Q2 2022, with the low at -$77.0 million in Q4 2022.
- A 5-year average of -$3.1 million and a median of -$7.9 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 2892.28% in 2022, down 522.04% in 2022.
- Lyra Therapeutics' Net Cash Flow stood at -$12.4 million in 2021, then tumbled by 522.04% to -$77.0 million in 2022, then jumped by 96.76% to -$2.5 million in 2023, then surged by 771.93% to $16.8 million in 2024, then plunged by 136.73% to -$6.2 million in 2025.
- The last three Net Cash Flow figures came in at -$6.2 million (Q4 2025), -$7.7 million (Q3 2025), and -$6.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.16 Mn |
| Dec 31, 2025 | -6.16 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Jun 30, 2025 | -6.59 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Mar 31, 2025 | -8.84 Mn |
| Dec 31, 2024 | 16.78 Mn |
| Dec 31, 2024 | 16.78 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Jun 30, 2024 | 16.11 Mn |
| Jun 30, 2024 | 16.11 Mn |
| Mar 31, 2024 | -5.95 Mn |
| Mar 31, 2024 | -5.95 Mn |
| Dec 31, 2023 | -2.50 Mn |
| Dec 31, 2023 | -2.50 Mn |
| Sep 30, 2023 | -29.51 Mn |
| Sep 30, 2023 | -29.51 Mn |